Navigation Links
Reportlinker Adds Prostate Cancer - Japan Drug Forecasts and Treatment Analysis to 2020
Date:12/8/2010

NEW YORK, Dec. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Prostate Cancer - Japan Drug Forecasts and Treatment Analysis to 2020

http://www.reportlinker.com/p0332356/Prostate-Cancer---Japan-Drug-Forecasts-and-Treatment-Analysis-to-2020.html

Prostate Cancer - Japan Drug Forecasts and Treatment Analysis to 2020

Summary

GlobalData's pharmaceutical report, "Prostate Cancer - Japan Drug Forecasts and Treatment Analysis to 2020" is an essential source of information and analysis on the Japanese prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the Japanese prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the Japanese prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized Japanese prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.

- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.

- Competitor assessment including drug launch analysis and drug sales forecasts.

- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.

- Analysis of unmet need in the market and target product profiles including opportunity for target products.

- Technology trends analytic framework to assess the strength of the pipeline.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.

- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.

- Analysis of the current and future market competition in the Japanese Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.

- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.

- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in Japan.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

- Develop business strategies and perform superior market quantification analysis by

- Understanding the trends shaping and driving the Japanese prostate cancer therapeutics market.

- Understanding the treatment preferences of physicians for each disease state and across treatment flow.

- Accessing market sizing forecasts and quantified growth opportunities in the Japanese prostate cancer therapeutics market up to 2020.

- Quantifying the patient population in the Japanese to better design product pricing and launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

- Performing benchmarking analysis and growth opportunities against currently marketed products.

- Identifying market entry points based on safety, efficacy, and pricing parameters.

- Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition.

- Develop and design your in-licensing and out-licensing strategies by

- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.

- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.

- Track drug sales in the Japanese prostate cancer therapeutics market from 2001 to 2020.

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What's the next big thing in the Japanese prostate cancer therapeutics market landscape? Identify, understand and capitalize.

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 8

2 Disease Overview 10

2.1 Overview 10

2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 10

2.1.2 Jewett-Whitmore system 11

2.2 Epidemiology 12

2.3 Etiology 12

2.4 Symptoms 12

2.4.1 Localized or Locally Advanced Prostate Cancer 12

2.4.2 Metastatic Prostate Cancer 13

2.5 Diagnosis 13

2.5.1 Digital Rectal Examination 13

2.5.2 Prostate Specific Antigen Test 14

2.5.3 Transrectal Ultrasound 14

2.5.4 Prostate Biopsy 14

2.6 Pathology 15

2.6.1 Grading 15

2.7 Treatment 15

2.7.1 Watchful Waiting 15

2.7.2 Radiation therapy 15

2.7.3 Surgery 16

2.7.4 Hormone therapy 17

2.7.5 Chemotherapy Options 18

2.7.6 Other Treatments Being Studied 18

2.8 Treatment Guidelines 19

3 Market Characterization 20

3.1 Japan 20

3.1.1 Market Size 20

3.1.2 Drivers and Barriers 25

3.1.3 Impact on the Market 26

3.1.4 Forecasts 27

3.1.5 Future Impact 32

3.1.6 Drug Sales 33

3.1.7 Pricing & Reimbursements 37

4 Competitor Assessment 38

4.1 Strategic Competitor Assessment 38

4.1.1 Overview 38

4.1.2 Benchmarking 39

4.1.3 Current Competitor Assessment 43

4.2 Launch Analysis and Sales Forecasts 45

4.3 Product Profiles 46

4.3.1 Taxotere (docetaxel) 47

4.3.2 Casodex (Bicalutamide) 51

4.3.3 Zoladex (Goserelin) 56

4.3.4 Lupron (Leuprolide acetate) 58

4.3.5 Firmagon (degarelix) 62

4.3.6 Novantrone (Mitoxantrone hydrochloride) 65

4.3.7 Emcyt (estramustine) 67

4.3.8 Trelstar (triptorelin) 69

4.3.9 Eulexin 70

4.3.10 Delestrogen 72

4.3.11 Gynodiol 74

4.3.12 Estrace tablet 75

4.3.13 Tace 76

4.3.14 Nilandrone 77

4.3.15 Premarin 78

4.3.16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 79

5 Pipeline Assessment 80

5.1 Overview 80

5.2 Pipeline Analysis by Phase of Development 81

5.3 Pipeline by Mechanism of Action 82

5.4 Strategic Pipeline Assessment 83

5.4.1 Technology Trends Analytical Framework 83

5.5 Trends in Prostate Cancer Pipeline 84

5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 84

5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 84

5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 84

5.6 Partners in Research and Development 85

5.6.1 Licensing Agreements by Phase of Development 85

5.6.2 Licensing Agreements by Geography 88

5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 88

5.7 Most Promising Drugs' Profiles 89

5.7.1 Provenge (sipuleucel-T) 91

5.7.2 Jevtana (cabazitaxel) 93

5.7.3 Aflibercept (VEGF Trap) 95

5.7.4 Ipilimumab 97

5.7.5 Abiraterone Acetate (CB7630) 100

5.7.6 Zibotentan (ZD4054) 102

5.7.7 Sprycel (dasatinib) 104

5.7.8 MDV3100 106

5.8 Prostate Cancer Pipeline – Pre-clinical Phase 109

5.9 Prostate Cancer Pipeline – Phase I 111

5.10 Prostate Cancer Pipeline – Phase II 114

5.11 Prostate Cancer Pipeline – Phase III 123

5.12 Key Takeaway 125

6 Unmet Need and Target Product Profile 126

6.1 Unmet Need 128

6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 128

6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 129

6.2 Opportunity for Target Product 130

6.3 Target Product Profile 132

6.3.1 Ideal Characteristics 132

6.3.2 Target Product Description 133

6.4 Key Takeaway 133

7 Strategic Assessment 134

7.1 Key Events Impacting the Future Market 134

7.2 Market Impact Analysis 135

7.3 Future Market Scenario 135

7.4 Company Analysis 137

7.4.1 Market Leadership 137

7.4.2 Future Players in the Market 137

7.5 Key Takeaway 138

8 Company Profiles 139

8.1 Sanofi-aventis 139

8.1.1 Business Description 139

8.1.2 Financial Overview 141

8.1.3 SWOT Analysis 141

8.1.4 Oncology Focus 146

8.2 Pfizer Inc. 147

8.2.1 Business Description 147

8.2.2 Financial Overview 148

8.2.3 SWOT Analysis 148

8.2.4 Oncology Focus 154

8.3 AstraZeneca 156

8.3.1 Business Description 156

8.3.2 Financial Overview 157

8.3.3 SWOT Analysis 158

8.3.4 Oncology Focus 162

8.4 Bristol-Myers Squibb 164

8.4.1 Business Description 164

8.4.2 Financial Overview 165

8.4.3 SWOT Analysis 165

8.4.4 Oncology Focus 171

8.5 Medivation 172

8.5.1 Business Description 172

8.5.2 SWOT Analysis 173

8.5.3 Oncology Focus 176

8.6 Takeda Pharmaceuticals 177

8.6.1 Business Description 177

8.6.2 SWOT Analysis 177

8.7 Dendreon Corporation 179

8.7.1 Business Description 179

8.7.2 SWOT Analysis 179

8.8 Johnson and Johnson 183

8.8.1 Business Description 183

8.8.2 SWOT Analysis 184

8.8.3 Oncology Focus 190

8.9 Auron Healthcare GmbH 191

8.9.1 Business Description 191

8.10 Oncogenex Pharmaceuticals, Inc. 192

8.10.1 Business Description 192

8.11 Agennix AG 192

8.11.1 Business Description 192

8.12 GTx, Inc. 192

8.12.1 Business Description 192

8.13 GlaxoSmithKline plc. 193

8.13.1 Business Description 193

8.13.2 Financial Overview 194

8.13.3 SWOT Analysis 194

8.13.4 Oncology Focus 200

9 M&A Analysis 202

9.1 Key Highlights 202

9.2 Key Deals' Analysis 203

9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 203

9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 203

9.2.3 Tolmar Holding Acquires QLT USA from QLT 204

9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 204

9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 205

9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 205

9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 205

9.2.8 GPC Biotech Merges with Agennix 205

9.2.9 Eli Lilly Acquires ImClone 205

9.2.10 BBM Holdings Acquires YM BioSciences 206

9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 206

9.3 M&A Deals by Geography 206

9.4 M&A Deals by Deal Size 207

10 Expert Opinion 208

10.1 Japan 208

11 Appendix 209

11.1 Market Definitions 209

11.2 Abbreviations 209

11.3 Research Methodology 211

11.3.1 Coverage 212

11.3.2 Secondary Research 212

11.3.3 Forecasting 212

11.3.4 Primary Research 215

11.3.5 Expert Panel validation 215

11.3.6 Contact Us 215

11.3.7 Disclaimer 215

11.3.8 Sources 2161.1 List of Tables

Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 11

Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 14

Table 3: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2001-2009 20

Table 4: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009 21

Table 5: Prostate Cancer Therapeutics Market, Japan, Patient Volume ('000s), 2001-2009 22

Table 6: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns ('000s), 2001-2009 23

Table 7: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2009-2020 27

Table 8: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2020 28

Table 9: Prostate Cancer Therapeutics Market, Japan, Patient Volume ('000s), 2009-2020 29

Table 10: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns ('000s), 2009-2020 30

Table 11: Prostate Cancer Therapeutics Market, Japan, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2010 34

Table 12: Prostate Cancer Therapeutics Market, Japan, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2011-2020 34

Table 13: Prostate Cancer Therapeutics Market, Japan, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2010 36

Table 14: Prostate Cancer Therapeutics Market, Japan, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2011-2020 36

Table 15: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 40

Table 16: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 41

Table 17: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 41

Table 18: Prostate Cancer, Japan, Benchmarking Major Marketed Products, 2010 46

Table 19: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 52

Table 20: Prostate Cancer, Global, Lupron, Efficacy End Point for Three Products 58

Table 21: Prostate Cancer, Global, Lupron, Incidence of Adverse Effects, 2010 59

Table 22: Prostate Cancer, Global, Licensing Agreements, 2009-2010 87

Table 23: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 89

Table 24: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 89

Table 25: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 109

Table 26: Prostate Cancer, Global, Phase I Pipeline, August 2010 111

Table 27: Prostate Cancer, Global, Phase II Pipeline, August 2010 114

Table 28: Prostate Cancer, Global, Phase III Pipeline, August 2010 123

Table 29: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 132

Table 30: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 133

Table 31: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 190

Table 32: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 191

Table 33: Prostate Cancer, Global, M&A Deals by Geography, 2010 2021.2

List of Figures

Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 19

Figure 2: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2001-2009 20

Figure 3: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009 21

Figure 4: Prostate Cancer Therapeutics Market, Japan, Patient Volume ('000s), 2001-2009 22

Figure 5: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns ('000s), 2001-2009 23

Figure 6: Prostate Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2009 25

Figure 7: Prostate Cancer Therapeutics Market, Japan, Historical Events Impact on the Market, 2010 26

Figure 8: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2009-2020 27

Figure 9: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2020 28

Figure 10: Prostate Cancer Therapeutics Market, Japan, Patient Volume ('000s), 2009-2020 29

Figure 11: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns ('000s), 2009-2020 30

Figure 12: Prostate Cancer Therapeutics Market, Japan, Future Events Expected to Impact the Market, 2010 32

Figure 13: Prostate Cancer Therapeutics Market, Japan, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2020 33

Figure 14: Prostate Cancer Therapeutics Market, Japan, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2020 35

Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 43

Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 44

Figure 17: Prostate Cancer Therapeutics Market, Japan, Sales Forecast by Therapies, 2001-2020 45

Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure 47

Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 49

Figure 20: Prostate Cancer, Japan, Taxotere, Sales ($m), 2004-2020 50

Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure 51

Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010 54

Figure 23: Prostate Cancer, Japan, Casodex, Sales ($m), 1999-2020 55

Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure 56

Figure 25: Prostate Cancer, Japan, Zoladex, Sales Forecast ($m), 2002-2020 57

Figure 26: Prostate Cancer, Global, Lupron, Chemical Structure 58

Figure 27: Prostate Cancer, Japan, Leuprolide (Lupron), Sales Forecast ($m), 2001-2020 61

Figure 28: Prostate Cancer, Global, Firmagon, Chemical Structure 62

Figure 29: Prostate Cancer, Japan, Firmagon, Sales Forecast ($m), 2009-2020 64

Figure 30: Prostate Cancer, Global, Novatrone, Chemical Structure 65

Figure 31: Prostate Cancer, Japan, Mitoxantrone, Sales Forecast ($m), 2001-2020 67

Figure 32: Prostate Cancer, Global, Emcyt, Chemical Structure 67

Figure 33: Prostate Cancer, Japan, Estramustine, Sales Forecast ($m), 2001-2020 68

Figure 34: Prostate Cancer, Global, Trelstar, Chemical Structure 69

Figure 35: Prostate Cancer, Global, Eulexin, Chemical Structure 70

Figure 36: Prostate Cancer, Global, Delestrogen, Chemical Structure 72

Figure 37: Prostate Cancer, Global, Gynodiol, Chemical Structure 74

Figure 38: Prostate Cancer, Global, Estrace, Chemical Structure 75

Figure 39: Prostate Cancer, Global, Tace, Chemical Structure 76

Figure 40: Prostate Cancer, Global, Nilandrone, Chemical Structure 77

Figure 41: Prostate Cancer, Global, Premarin, Chemical Structure 78

Figure 42: Prostate Cancer, Japan, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 79

Figure 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 80

Figure 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 81

Figure 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 82

Figure 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 83

Figure 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 84

Figure 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 85

Figure 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 88

Figure 50: Prostate Cancer, Japan, Provenge, Sales Forecast ($m), 2016-2020 92

Figure 51: Prostate Cancer, Japan, Jevtana, Sales Forecast ($m), 2013-2020 94

Figure 52: Prostate Cancer, Global, Aflibercept, Chemical Structure 95

Figure 53: Prostate Cancer, Japan, Aflibercept, Sales Forecast ($m), 2016-2020 97

Figure 54: Prostate Cancer, Japan, Ipilimumab , Sales Forecast ($m), 2014-2020 99

Figure 55: Prostate Cancer, Global, Abiraterone, Chemical Structure 100

Figure 56: Prostate Cancer, Japan, Abiraterone, Sales Forecast ($m), 2015-2020 102

Figure 57: Prostate Cancer, Global, Zibotentan, Chemical Structure 102

Figure 58: Prostate Cancer, Japan, Zibotentan , Sales Forecast ($m), 2015-2020 104

Figure 59: Prostate Cancer, Japan, Sprycel , Sales Forecast ($m), 2013-2020 105

Figure 60: Prostate Cancer, Global, MDV3100, Chemical Structure 106

Figure 61: Prostate Cancer, Japan, MDV3100 , Sales Forecast ($m), 2015-2020 108

Figure 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 126

Figure 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 127

Figure 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 127

Figure 65: Prostate Cancer, Japan, Prostate Cancer, Opportunity and Unmet Need, 2010 128

Figure 66: Prostate Cancer, Japan, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 131

Figure 67: Prostate Cancer, Japan, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 132

Figure 68: Prostate Cancer, Global, Key Events Impacting the Future Market 134

Figure 69: Prostate Cancer, Japan, Implications for Future Market Competition, 2010 135

Figure 70: Prostate Cancer, Global, Future Players in the Market, 2010 137

Figure 71:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 139

Figure 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 140

Figure 73: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 141

Figure 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 146

Figure 75: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 148

Figure 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 154

Figure 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 155

Figure 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 157

Figure 79: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 158

Figure 80: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 162

Figure 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 162

Figure 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 163

Figure 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 164

Figure 84: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 165

Figure 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 171

Figure 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 172

Figure 87: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 173

Figure 88: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010 177

Figure 89: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 179

Figure 90: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 184

Figure 91: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 191

Figure 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 194

Figure 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 200

Figure 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 201

Figure 95: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 206

Figure 96: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 207

Figure 97: Prostate Cancer, Japan, Key Data Inputs from KOL Interviews, July 2010 208

Figure 98: GlobalData Market Forecasting Model 214

Companies mentioned

Sanofi-aventis

Pfizer Inc.

AstraZeneca

Bristol-Myers Squibb

Medivation

Takeda Pharmaceuticals

Dendreon Corporation

Johnson and Johnson

Auron Healthcare GmbH

Oncogenex Pharmaceuticals, Inc.

Agennix AG

GTx, Inc.

GlaxoSmithKline plc.

To order this report:

Drug and Medication Industry: Prostate Cancer - Japan Drug Forecasts and Treatment Analysis to 2020

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Global Syringes (Disposable and Reusable) Industry
2. Reportlinker Adds US Prebiotics Industry
3. Reportlinker Adds Global Biosimilars (Follow-on biologics) Market: An Analysis
4. Reportlinker Adds TOP 10 DRUG DISCOVERY TECHNOLOGIES - STRATEGIC ANALYSIS AND GLOBAL FORECASTS
5. Reportlinker Adds Global HPLC Systems & Accessories Industry
6. Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry
7. Reportlinker Adds Global Freeze Drying Equipment Industry
8. Reportlinker Adds Global Surgical Incision Closures Industry
9. Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
10. Reportlinker Adds Global Uro-Gynecological Surgical Devices Industry
11. Reportlinker Adds Global Sterilization Systems & Equipment Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 ... alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response ... and tolerability profile of ropeginterferon alfa-2b versus HU ... ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing authorization ... present this data to the FDA as it seeks approval ...
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016 Johnson ... filed on behalf of purchasers of Zimmer Biomet Holdings, Inc. ... September 7, 2016 through October 31, 2016 (the "Class Period"). ... It designs, manufactures, and markets orthopaedic reconstructive products, such as ... ...
(Date:12/4/2016)... 3, 2016   Pairnomix, LLC, a genetic research ... recognized by the White House, today announced that findings from ... identification of candidate therapies for a patient with epileptic encephalopathy ... were presented at the 70 th Annual Meeting of ... TX , December 2-6, 2016.  Pairnomix, unique ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... 05, 2016 , ... BSI and Brenntag Canada have been appointed by Chr. ... of their natural fruits and beverage colorants effective November 1, 2016. ... our Life Sciences product portfolio,” said Steve Brauer, President of Brenntag Specialties, Inc. “Representing ...
(Date:12/5/2016)... , ... December 05, 2016 ... ... Great Point Partners ("GPP") portfolio company, today announced it has acquired the ... TCS was previously a subsidiary of Chiltern International and focuses on ...
(Date:12/5/2016)... ... ... The new knee compression sleeves come as a pair which will provide ... lifting and any sport that requires knee compression or protection from the demands ... higher quality knee sleeve performance. Firstly it is made out of premium 7mm thick ...
(Date:12/5/2016)... OH (PRWEB) , ... December 05, 2016 , ... ... engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy of ... in various healthcare settings. , Over the last 60 years, studies have ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... "Best Surgical Body Shaping" at the 2016 Anti-Aging & Beauty Awards ... , The Aesthetic & Anti-Aging Medicine European Congress (AMEC) brings together ...
Breaking Medicine News(10 mins):